Please login to the form below

Advanced Accelerator Applications

This page shows the latest Advanced Accelerator Applications news and features for those working in and with pharma, biotech and healthcare.

Novartis chooses internal replacement for US pharma president role

She joined the company from Advanced Accelerator Applications after it was acquired by Novartis and has also served as the head of pharmaceuticals for Europe at the company.

Latest news

Novartis buys cancer specialist Endocyte for $2.1bn

177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.
Novartis follows Pfizer and freezes US prices this year

ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit.
AAA board presses go on $3.9bn Novartis takeover

French radiopharmaceuticals firm backs the cash offer. Novartis has started its cash tender offer for French firm Advanced Accelerator Applications, which specialises in radiopharmaceuticals to treat cancer.
Novartis to buy French radiopharma specialist AAA for $3.9bn

Novartis has agreed a $3.9bn deal to buy Advanced Accelerator Applications, a French company specialising in nuclear medicines used to treat tumours. ... The transaction gives Novartis “both near-term product launches as well as a new technology
AAA’s orphan drug Lutathera wins EU green light

The first-in-class drug treats adults with GEP-NET. Advanced Accelerator Applications’ (AAA) Lutathera (lutetium oxodotreotide) has received European approval to treat adults with unresectable or metastatic, somatostatin receptor positive

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

Abeona Therapeutics appoints new additions to board of directors

Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.
Former Roche development head joins Asana advisory board

The founder of KAPital Consulting, Dr Dhingra currently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications, Five Prime and Autolus.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

3 Monkeys Zeno

If you’d like to know more healthcare@3monkeyszeno.com Or visit; Merck, Bayer, Boehringher Ingelheim, Novartis, Hologic, Netflix, SilverCloud, Advanced Accelerator Applications, Perrigo.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Healthcare Communications: Salary TBC

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...